OTC Markets OTCQB • USD
Aequus Pharmaceuticals Inc. (AQSZF)
At close: May 29 at 9:30 AM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Douglas Glen Janzen | Chairman, CEO & President | 149.68k | -- | 1969 |
| Ms. Ann Fehr CGA, CPA | CFO & Corporate Secretary | 98.8k | -- | 1969 |
| Mr. Grant Larsen | Chief Commercial Officer | 177.5k | -- | -- |
Aequus Pharmaceuticals Inc.
200 Granville Street
Suite 2820
Vancouver, BC V6C 1S4
Canada
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Corporate Governance
Aequus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 27, 2024 at 8:00 PM UTC - September 2, 2024 at 8:00 PM UTC
Aequus Pharmaceuticals Inc. Earnings Date
Recent Events
Recent Events Information Not Available